Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model (OS-TUMOVASC)
Sponsor: Central Hospital, Nancy, France
Listed as NCT05136014, this observational or N/A phase trial focuses on EGFR Activating Mutation and KRAS Mutation-Related Tumors and remains ongoing. Sponsored by Central Hospital, Nancy, France, it has been updated 5 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2023 — Jul 2024 [monthly]
Unknown Status
Status: Enrolling By Invitation → Unknown Status
-
Dec 2021 — Dec 2023 [monthly]
Enrolling By Invitation
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Central Hospital, Nancy, France
- Institut de Cancérologie de Lorraine
For direct contact, visit the study record on ClinicalTrials.gov .